

Title (en)

HIGHLY CONCENTRATED LIQUID FORMULATIONS OF ANTI-EGFR ANTIBODIES

Title (de)

HOCHKONZENTRIERTE, FLÜSSIGE FORMULIERUNGEN VON ANTI-EGFR-ANTIKÖRPERN

Title (fr)

FORMULATIONS LIQUIDES FORTEMENT CONCENTREES D'ANTICORPS ANTI-EGFR

Publication

EP 1713502 A1 20061025 (DE)

Application

EP 05701212 A 20050127

Priority

- EP 2005000797 W 20050127
- US 54354904 P 20040212

Abstract (en)

[origin: WO2005077414A1] The invention relates to methods for producing, by ultrafiltration, highly concentrated liquid formulations containing at least one anti-EGFR antibody and/or one of its variants and/or fragments, particularly monoclonal antibodies against the EGF receptor, particularly preferred Mab C225 (cetuximab) and Mab h425 (EMD 72000). The invention also relates to highly concentrated liquid formulations of anti-EGFR antibodies, particularly monoclonal antibodies against the EGF receptor, particularly preferred Mab C225 (cetuximab) and Mab h425 (EMD 72000) and/or their variants and/or fragments. The invention is characterized in that the highly concentrated liquid formulations have a content of anti-EGFR antibodies ranging from 10 to 250, preferably from 50 to 180 mg/ml, particularly preferred from 100 to 150 mg/ml. Finally, the invention relates to the use of these formulations.

IPC 8 full level

A61K 39/395 (2006.01); **A61K 9/00** (2006.01); **A61K 9/08** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP KR US)

A61K 9/08 (2013.01 - EP US); **A61K 39/395** (2013.01 - KR); **A61P 3/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **C07K 16/2863** (2013.01 - EP US)

Citation (search report)

See references of WO 2005077414A1

Citation (examination)

- HARDING JOANNE ET AL: "Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody.", DRUGS OF TODAY (BARCELONA, SPAIN : 1998) FEB 2005 LNKD- PUBMED:15821783, vol. 41, no. 2, February 2005 (2005-02-01), pages 107 - 127, ISSN: 1699-3993
- SUSANNE MATHEUS ET AL: "A Critical Evaluation of Tm(FTIR) Measurements of High-Concentration IgG1 Antibody Formulations as a Formulation Development Tool", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 23, no. 7, 21 June 2006 (2006-06-21), pages 1617 - 1627, XP019405151, ISSN: 1573-904X, DOI: 10.1007/S11095-006-0283-9
- "Protein Concentration and Diafiltration by Tangential Flow Filtration", 2003, Retrieved from the Internet <URL:http://www.millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/ab3ba3a9d06cc6f185256bd10068b0de/\$FILE/TB032.pdf> [retrieved on 20111201]
- SRIDHAR S S ET AL: "Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 4, no. 7, 1 July 2003 (2003-07-01), pages 397 - 406, XP004809825, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(03)01137-9
- FRACASSO-PM ET AL: "A study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of a single infusion of cetuximab (IMC-C225).", PROC AM SOC CLIN ONCOL, vol. 22, 1 December 2011 (2011-12-01) - 2003, (ABSTR 787)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

YU

DOCDB simple family (publication)

WO 2005077414 A1 20050825; AR 047611 A1 20060125; AU 2005211890 A1 20050825; AU 2005211890 B2 20110728; BR PI0507608 A 20070703; CA 2555791 A1 20050825; CN 1953768 A 20070425; CN 1953768 B 20101013; EP 1713502 A1 20061025; HK 1103281 A1 20071214; JP 2007522157 A 20070809; KR 101342735 B1 20131219; KR 20060121956 A 20061129; KR 20120089307 A 20120809; RU 2006132466 A 20080320; RU 2390353 C2 20100527; US 2007172475 A1 20070726; US 2012076784 A1 20120329; ZA 200607600 B 20080430

DOCDB simple family (application)

EP 2005000797 W 20050127; AR P050100492 A 20050211; AU 2005211890 A 20050127; BR PI0507608 A 20050127; CA 2555791 A 20050127; CN 200580004883 A 20050127; EP 05701212 A 20050127; HK 07107314 A 20070709; JP 2006552493 A 20050127; KR 20067016023 A 20060809; KR 20127011256 A 20050127; RU 2006132466 A 20050127; US 201113311097 A 20111205; US 58845805 A 20050127; ZA 200607600 A 20060911